229 related articles for article (PubMed ID: 19151751)
1. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.
Yang XY; Guan M; Vigil D; Der CJ; Lowy DR; Popescu NC
Oncogene; 2009 Mar; 28(11):1401-9. PubMed ID: 19151751
[TBL] [Abstract][Full Text] [Related]
2. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
3. SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP.
Chau JE; Vish KJ; Boggon TJ; Stiegler AL
Nat Commun; 2022 Aug; 13(1):4788. PubMed ID: 35970859
[TBL] [Abstract][Full Text] [Related]
4. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
Cao X; Voss C; Zhao B; Kaneko T; Li SS
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Point Mutations in the
Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
[TBL] [Abstract][Full Text] [Related]
7. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
9. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
11. CDK5 is a major regulator of the tumor suppressor DLC1.
Tripathi BK; Qian X; Mertins P; Wang D; Papageorge AG; Carr SA; Lowy DR
J Cell Biol; 2014 Dec; 207(5):627-42. PubMed ID: 25452387
[TBL] [Abstract][Full Text] [Related]
12. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.
Erlmann P; Schmid S; Horenkamp FA; Geyer M; Pomorski TG; Olayioye MA
Mol Biol Cell; 2009 Oct; 20(20):4400-11. PubMed ID: 19710422
[TBL] [Abstract][Full Text] [Related]
13. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
15. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
16. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
18. An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase.
Hildebrand JD; Taylor JM; Parsons JT
Mol Cell Biol; 1996 Jun; 16(6):3169-78. PubMed ID: 8649427
[TBL] [Abstract][Full Text] [Related]
19. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.
Ullmannova-Benson V; Guan M; Zhou X; Tripathi V; Yang XY; Zimonjic DB; Popescu NC
Leukemia; 2009 Feb; 23(2):383-90. PubMed ID: 18923442
[TBL] [Abstract][Full Text] [Related]
20. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
